Manufacturing company Nordson (NASDAQ:NDSN) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 2.8% year on year to $615.4 million. Next quarter’s revenue guidance of $670 million underwhelmed, coming in 2.5% below analysts’ estimates. Its non-GAAP profit of $2.06 per share was 0.9% below analysts’ consensus estimates.
Palantir stock fell more than 10% Wednesday following a report the Trump administration is planning deep cuts to the defense budget.
Online money transfer platform Remitly (NASDAQ:RELY) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 32.9% year on year to $351.9 million. The company expects next quarter’s revenue to be around $346.5 million, close to analysts’ estimates. Its GAAP loss of $0.03 per share was 67.6% above analysts’ consensus estimates.
Carvana reported fourth quarter earnings after the bell on Wednesday.
Health and wellness products company Herbalife (NYSE:HLF) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.21 billion. On the other hand, next quarter’s revenue guidance of $1.22 billion was less impressive, coming in 4.2% below analysts’ estimates. Its non-GAAP profit of $0.36 per share was significantly above analysts’ consensus estimates.
Restaurant company Cheesecake Factory (NASDAQ:CAKE) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 5% year on year to $921 million. Its non-GAAP profit of $1.04 per share was 13.7% above analysts’ consensus estimates.
Morgan Stanley said the market has overlooked the giant retailer's profit margins, which could be reinvested in making its e-commerce businesses even more efficient.
Conveyorized car wash service company Mister Car Wash (NYSE:MCW) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $251.2 million. On the other hand, the company’s full-year revenue guidance of $1.05 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $0.09 per share was 25.1% above analysts’ consensus estimates.
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 billion, close to analysts’ estimates. Its non-GAAP loss of $0.06 per share was 67.9% above analysts’ consensus estimates.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 24.6% above analysts’ consensus estimates.
